Structure Therapeutics (GPCR) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $21.08, -5.00% vs the prior close of $22.19.
- Volume 1.16M shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
GPCR slides 5.0% to $21.08, a 52-week low. Closed at $21.08, -5.00% vs the prior close of $22.19. Day range $20.73–$22.20, opened at $22.15.
GPCR daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — GPCR slides 5.0% to $21.08, a 52-week low
- Closed at $21.08, -5.00% vs the prior close of $22.19. Day range $20.73–$22.20, opened at $22.15.
- Volume was 1.16M shares, 1.0x its 50-day average of 1.16M.
- Price is -47.0% vs its 50-day average ($39.76) and -59.0% vs its 200-day average ($51.46).
- 52-week range $20.73–$94.90; today's close sits at 0% of that range, 77.8% below the 52-week high.
Oct 15, 2026 — GPCR rises 1.4% to $22.19
- Closed at $22.19, +1.42% vs the prior close of $21.88. Day range $21.81–$22.61, opened at $21.89.
- Volume was 1.41M shares, 1.2x its 50-day average of 1.15M.
- Price is -45.1% vs its 50-day average ($40.39) and -57.1% vs its 200-day average ($51.69).
- 52-week range $21.55–$94.90; today's close sits at 1% of that range, 76.6% below the 52-week high.
Oct 14, 2026 — GPCR dips 1.9% to $21.88, a 52-week low on 1.8x normal volume
- Closed at $21.88, -1.93% vs the prior close of $22.31. Day range $21.55–$22.89, opened at $22.46.
- Volume was 2.07M shares, 1.8x its 50-day average of 1.12M — unusually heavy trading.
- Price is -46.6% vs its 50-day average ($40.96) and -57.9% vs its 200-day average ($51.92).
- 52-week range $21.55–$94.90; today's close sits at 0% of that range, 76.9% below the 52-week high.
- That makes 14 straight losses.
Oct 13, 2026 — GPCR slides 6.7% to $22.31, a 52-week low, 13 down days in a row
- Closed at $22.31, -6.69% vs the prior close of $23.91. Day range $22.10–$24.03, opened at $23.92.
- Volume was 1.43M shares, 1.3x its 50-day average of 1.10M.
- Price is -46.3% vs its 50-day average ($41.51) and -57.2% vs its 200-day average ($52.15).
- 52-week range $22.10–$94.90; today's close sits at 0% of that range, 76.5% below the 52-week high.
- That makes 13 straight losses.
Oct 12, 2026 — GPCR slides 6.4% to $23.91, a 52-week low, 12 down days in a row
- Closed at $23.91, -6.38% vs the prior close of $25.54. Day range $23.89–$25.50, opened at $25.25.
- Volume was 1.66M shares, 1.5x its 50-day average of 1.08M.
- Price is -43.1% vs its 50-day average ($42.03) and -54.4% vs its 200-day average ($52.38).
- 52-week range $23.89–$94.90; today's close sits at 0% of that range, 74.8% below the 52-week high.
- That makes 12 straight losses.
Oct 9, 2026 — GPCR dips 0.5% to $25.54, a 52-week low, 11 down days in a row
- Closed at $25.54, -0.51% vs the prior close of $25.67. Day range $25.29–$26.15, opened at $25.73.
- Volume was 592.80K shares, 0.6x its 50-day average of 1.07M — lighter than usual.
- Price is -39.9% vs its 50-day average ($42.52) and -51.5% vs its 200-day average ($52.62).
- 52-week range $25.09–$94.90; today's close sits at 1% of that range, 73.1% below the 52-week high.
- That makes 11 straight losses.
Oct 8, 2026 — GPCR slides 3.8% to $25.67, a 52-week low, 10 down days in a row
- Closed at $25.67, -3.79% vs the prior close of $26.68. Day range $25.09–$26.80, opened at $26.57.
- Volume was 939.20K shares, 0.9x its 50-day average of 1.06M.
- Price is -40.3% vs its 50-day average ($43.00) and -51.4% vs its 200-day average ($52.81).
- 52-week range $25.09–$94.90; today's close sits at 1% of that range, 73.0% below the 52-week high.
- That makes 10 straight losses.
Oct 7, 2026 — GPCR dips 2.9% to $26.68, a 6-month low, 9 down days in a row
- Closed at $26.68, -2.88% vs the prior close of $27.47. Day range $26.38–$28.05, opened at $27.14.
- Volume was 1.05M shares, 1.0x its 50-day average of 1.05M.
- Price is -38.6% vs its 50-day average ($43.43) and -49.7% vs its 200-day average ($53.01).
- 52-week range $25.59–$94.90; today's close sits at 2% of that range, 71.9% below the 52-week high.
- That makes 9 straight losses.
Oct 6, 2026 — GPCR dips 0.4% to $27.47, a 6-month low, 8 down days in a row
- Closed at $27.47, -0.43% vs the prior close of $27.59. Day range $26.69–$27.85, opened at $27.55.
- Volume was 1.42M shares, 1.4x its 50-day average of 1.03M.
- Price is -37.4% vs its 50-day average ($43.85) and -48.4% vs its 200-day average ($53.19).
- 52-week range $25.59–$94.90; today's close sits at 3% of that range, 71.1% below the 52-week high.
- That makes 8 straight losses.
Oct 5, 2026 — GPCR ends flat (-0.3%) to $27.59, a 6-month low on 1.9x normal volume
- Closed at $27.59, -0.29% vs the prior close of $27.67. Day range $26.41–$28.20, opened at $28.10.
- Volume was 1.87M shares, 1.9x its 50-day average of 1.01M — unusually heavy trading.
- Price is -37.7% vs its 50-day average ($44.28) and -48.3% vs its 200-day average ($53.35).
- 52-week range $25.59–$94.90; today's close sits at 3% of that range, 70.9% below the 52-week high.
- That makes 7 straight losses.
Oct 2, 2026 — GPCR slides 4.5% to $27.67, a 6-month low, 6 down days in a row
- Closed at $27.67, -4.52% vs the prior close of $28.98. Day range $27.57–$29.25, opened at $28.99.
- Volume was 1.71M shares, 1.7x its 50-day average of 987.98K.
- Price is -38.1% vs its 50-day average ($44.71) and -48.3% vs its 200-day average ($53.52).
- 52-week range $25.59–$94.90; today's close sits at 3% of that range, 70.8% below the 52-week high.
- That makes 6 straight losses.
GPCR latest news & SEC filings
Every SEC filing by or about GPCR in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 22, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Coll Crespo Blas had withheld for taxes 10,626 shares at $11.67 (≈$124.01K) on Sep 18, 2026; now holds 270,252
- Coll Crespo Blas converted 12,024 shares on Sep 21, 2026; now holds 258,228
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 21, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 19, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 7, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$106.16M (prior year -$61.66M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.49 (prior year -$0.36) (loss widened vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 6, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade GPCR
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Feb 26, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.16% (largest 7.3%). That is a volatile stock.
- Liquidity: about 1.49M shares (≈$31.46M) trade per day on average.
- 52-week position: $21.08 vs a range of $20.73–$94.90 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Sep 8, 2026; 10-Q Aug 6, 2026; 8-K Aug 6, 2026.
- Share count: 213.93M shares outstanding (Jul 31, 2026), +23.8% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
GPCR market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 22.15 | 22.20 | 20.73 | 21.08 | 1.16M |
| Oct 15, 2026 | 21.89 | 22.61 | 21.81 | 22.19 | 1.41M |
| Oct 14, 2026 | 22.46 | 22.89 | 21.55 | 21.88 | 2.07M |
| Oct 13, 2026 | 23.92 | 24.03 | 22.10 | 22.31 | 1.43M |
| Oct 12, 2026 | 25.25 | 25.50 | 23.89 | 23.91 | 1.66M |
| Oct 9, 2026 | 25.73 | 26.15 | 25.29 | 25.54 | 592.80K |
| Oct 8, 2026 | 26.57 | 26.80 | 25.09 | 25.67 | 939.20K |
| Oct 7, 2026 | 27.14 | 28.05 | 26.38 | 26.68 | 1.05M |
| Oct 6, 2026 | 27.55 | 27.85 | 26.69 | 27.47 | 1.42M |
| Oct 5, 2026 | 28.10 | 28.20 | 26.41 | 27.59 | 1.87M |
| Oct 2, 2026 | 28.99 | 29.25 | 27.57 | 27.67 | 1.71M |
| Oct 1, 2026 | 31.27 | 31.39 | 28.93 | 28.98 | 2.59M |
| Sep 30, 2026 | 33.05 | 33.05 | 31.08 | 31.27 | 2.20M |
| Sep 29, 2026 | 34.78 | 34.93 | 32.44 | 32.69 | 1.73M |
| Sep 28, 2026 | 34.86 | 35.64 | 34.43 | 35.06 | 1.28M |
| Sep 25, 2026 | 36.29 | 37.20 | 35.50 | 35.93 | 1.59M |
| Sep 24, 2026 | 35.35 | 36.27 | 34.43 | 36.02 | 2.11M |
| Sep 23, 2026 | 36.50 | 37.30 | 34.96 | 35.95 | 1.40M |
| Sep 22, 2026 | 36.99 | 37.74 | 36.25 | 36.91 | 611.20K |
| Sep 21, 2026 | 35.34 | 36.99 | 35.00 | 36.81 | 1.02M |
About Structure Therapeutics
Structure Therapeutics (GPCR) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SOUTH SAN FRANCISCO, CA. State of incorporation: Cayman Islands. Fiscal year ends December 31. SEC CIK 1888886.
GPCR board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Eric Dobmeier | Director | Jun 18, 2026 |
| Ted W Love | Director | Jun 18, 2026 |
| Angus C. Russell | Director | Jun 18, 2026 |
| Raymond C Stevens | CHIEF EXECUTIVE OFFICER | Mar 23, 2026 |
| Sharon Tetlow | Director | Jun 18, 2026 |
| Daniel G Welch | Director | Jun 18, 2026 |
| Joanne Waldstreicher | Director | Jun 18, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| John Joseph Berrios | Chief Commercial Officer | Aug 7, 2026 |
| Crespo Blas Coll | CHIEF MEDICAL OFFICER | Sep 22, 2026 |
| Ashley Hall | Chief Development Officer | Mar 23, 2026 |
| Matthew Lang | COO & GC | Apr 23, 2026 |
| Xichen Lin | CHIEF SCIENTIFIC OFFICER | Sep 2, 2026 |
| Yingli Ma | CHIEF TECHNOLOGY OFFICER | Mar 23, 2026 |
| Raymond C Stevens | CHIEF EXECUTIVE OFFICER | Mar 23, 2026 |
| Jun Yoon | CHIEF FINANCIAL OFFICER | Mar 23, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
GPCR financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-141.20M | -0.80 | $-222.20M |
| Dec 31, 2024 | — | $-122.53M | -0.78 | $-116.64M |
| Dec 31, 2023 | — | $-89.62M | -0.81 | $-79.49M |
| Dec 31, 2022 | — | $-51.32M | -5.51 | $-46.12M |
Latest balance sheet: total assets $1.43B, total liabilities $71.01M, cash $272.64M (as of Jun 30, 2026).
GPCR earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $52.62 |
| May 7, 2026 | 8-K Item 2.02 (results) | $39.15 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $64.75 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $33.47 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $16.31 |
| May 8, 2025 | 8-K Item 2.02 (results) | $26.82 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $22.82 |
| Nov 13, 2024 | 8-K Item 2.02 (results) | $36.37 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Mar 8, 2024 | 8-K Item 2.02 (results) | — |
| Nov 14, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on GPCR
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.